Coronado Industries Receives Speculative Buy Recommendation From Donner Corp. International.

Business Editors

FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--April 26, 2001

Coronado Industries (OTC BB: CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, today announced that it has received a Speculative Buy recommendation from Donner Corp. International, an investment banking firm located in Santa Ana, California. Donner issued the recommendation in a report issued yesterday.

The report, which can be found at www.donnercorp.com, highlighted Coronado's management team and strategic partnerships.

"One of Coronado's main strengths lies in the expertise and leadership of its staff. The Company's Clinical Studies Director, Dr. Leo Bores, who also heads the Company's FDA compliance division, is the world-renowned co-originator of Radial Keratotomy (RK), and one of the main driving forces behind the development of the Company's revolutionary Pneumatic Trabeculoplasty (PNT(TM))," the report states. "Dr. Bores' illustrious career has resulted in the implementation of many state-of-the-art instruments and techniques used in the field of Radial Keratotomy today, including the Bores' RK Method. In addition, Dr. Bores is responsible for performing the first KMIS (ALK) procedures for myopia and hyperopia in the United States. Dr. Bores has taught nearly every American eye surgeon currently performing RK, either personally or through his students."

The report continued, "With its recent agreement with CIBA Vision / Novartis (NYSE: NVS), the Company has made significant progress on its path toward the licensing and distribution of its glaucoma treatment system."

Richard Smith, President of Coronado Industries, commented: "This report sends a strong message to our loyal shareholders. It validates our ability to succeed, both in the medical technology industry, and in the financial community as well."

Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Ophthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT(TM)), a non-invasive, highly effective, and low-cost alternative to traditional treatments for glaucoma.

Currently, the Company is allowed to market its pneumatic suction device and treatment throughout the European marketplace under a CE Mark (allowing manufacturers to freely sell their products) from the European Commission. Pending FDA approval, the Company will license its patented treatment procedure and equipment in the United States.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

For additional information: www.coronadoindustries.com